Treating Moderate Plaque Psoriasis: Prospective 6-Month Chart Review of Patients Treated With Apremilast.

CONCLUSIONS: Most patients with moderate psoriasis receiving apremilast had improved at 6-month follow-up. Safety and tolerability were consistent with the safety profile of apremilast. PMID: 30339049 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/30339049?dopt=Abstract

Source: Journal of Dermatological Treatment - October 21, 2018 Category: Dermatology Tags: J Dermatolog Treat Source Type: research